Summit Securities Group’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
– Sell
-1,000
Closed -$763K – 1147
2025
Q3
$763K Buy
+1,000
New +$744K 0.16% 131
2021
Q1
– Sell
-20
Closed -$338K – 684
2020
Q4
$338K Buy
+20
New +$2.99K 0.03% 432
2020
Q3
– Sell
-115
Closed -$1.89M – 439
2020
Q2
$1.89M Buy
+115
New +$17.7K 0.23% 88
2019
Q2
– Sell
-1,514
Closed -$19.6M – 359
2019
Q1
$19.6M Buy
+1,514
New +$184K 3.59% 6

Other funds holding LLY

Summit Securities Group's LLY Position: Q3 2026 in Review

Summit Securities Group reduced its Eli Lilly (LLY) stake by 83% in Q3 2026, selling an estimated $199K and leaving 34 shares worth $39.3K. The position accounts for ﹤0.01% of the portfolio, ranked #613.

Summit Securities Group first reported a position in LLY in Q2 2013 and has held it in 30 quarters since. The position peaked at $3.17M in Q3 2021. 4,106 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Summit Securities Group held 34 shares of Eli Lilly worth $39.3K as of Q3 2026.
  • Summit Securities Group sold 169 Eli Lilly shares in Q3 2026, an estimated $199K.
  • Eli Lilly made up ﹤0.01% of Summit Securities Group's portfolio in Q3 2026, its #613 holding.
  • Summit Securities Group first reported a position in Eli Lilly in Q2 2013 and has held it in 30 quarters since.
  • Summit Securities Group's Eli Lilly position peaked at $3.17M in Q3 2021.
  • 4,106 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Summit Securities Group's 13F filing for Q3 2026, filed 5 Nov 2026.